Protocol Ledger

NCT04474847 · Phase III · RECRUITING

Abatacept for the Treatment of Giant Cell Arteritis

Interventional Phase III clinical trial protocol NCT04474847 sponsored by University of Pennsylvania in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-03-29 Enrollment: 78 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04474847
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)78 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04474847
Protocol FieldVerified Registry Value
NCT IdentifierNCT04474847
Consolidated Lead SponsorUniversity of Pennsylvania
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment78 participants (ESTIMATED)
Registered Start Date2021-03-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04474847
Hospital Research SiteLocationSite Profile
Mayo Clinic RochesterRochester, MNOpen Hospital Dossier ->
Cleveland ClinicCleveland, OHOpen Hospital Dossier ->
University of Pennsylvania Abramson Cancer CenterPhiladelphia, PAOpen Hospital Dossier ->
Vanderbilt University Medical CenterNashville, TNOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Penn Medicine (University of Pennsylvania) across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI